Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vivo emergence of resistance to ceftazidime/avibactam through modification of chromosomal AmpC β-lactamase in Klebsiella aerogenes.
Rodríguez-Pallares S, Blanco-Martín T, Lence E, Aja-Macaya P, Sánchez-Peña L, González-Pinto L, Rodríguez-Mayo M, Fernández-González A, Galán-Sánchez F, Beceiro A, González-Bello C, Bou G, Arca-Suárez J. Rodríguez-Pallares S, et al. Among authors: beceiro a. Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0130724. doi: 10.1128/aac.01307-24. Epub 2024 Nov 6. Antimicrob Agents Chemother. 2024. PMID: 39503481
Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
Arca-Suárez J, Fraile-Ribot P, Vázquez-Ucha JC, Cabot G, Martínez-Guitián M, Lence E, González-Bello C, Beceiro A, Rodríguez-Iglesias M, Galán-Sánchez F, Bou G, Oliver A. Arca-Suárez J, et al. Among authors: beceiro a. Antimicrob Agents Chemother. 2019 Sep 23;63(10):e01110-19. doi: 10.1128/AAC.01110-19. Print 2019 Oct. Antimicrob Agents Chemother. 2019. PMID: 31383659 Free PMC article.
Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection.
Arca-Suárez J, Vázquez-Ucha JC, Fraile-Ribot PA, Lence E, Cabot G, Martínez-Guitián M, Lasarte-Monterrubio C, Rodríguez-Iglesias M, Beceiro A, González-Bello C, Galán-Sánchez F, Oliver A, Bou G. Arca-Suárez J, et al. Among authors: beceiro a. J Antimicrob Chemother. 2020 Nov 1;75(11):3209-3217. doi: 10.1093/jac/dkaa291. J Antimicrob Chemother. 2020. PMID: 32728723
Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
Arca-Suárez J, Lasarte-Monterrubio C, Rodiño-Janeiro BK, Cabot G, Vázquez-Ucha JC, Rodríguez-Iglesias M, Galán-Sánchez F, Beceiro A, González-Bello C, Oliver A, Bou G. Arca-Suárez J, et al. Among authors: beceiro a. J Antimicrob Chemother. 2021 Jan 1;76(1):91-100. doi: 10.1093/jac/dkaa396. J Antimicrob Chemother. 2021. PMID: 33083833
Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Ruedas-López A, Alonso-García I, Lasarte-Monterrubio C, Guijarro-Sánchez P, Gato E, Vázquez-Ucha JC, Vallejo JA, Fraile-Ribot PA, Fernández-Pérez B, Velasco D, Gutiérrez-Urbón JM, Oviaño M, Beceiro A, González-Bello C, Oliver A, Arca-Suárez J, Bou G. Ruedas-López A, et al. Among authors: beceiro a. Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0206721. doi: 10.1128/AAC.02067-21. Epub 2021 Dec 20. Antimicrob Agents Chemother. 2022. PMID: 34930034 Free PMC article.
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Lasarte-Monterrubio C, Fraile-Ribot PA, Vázquez-Ucha JC, Cabot G, Guijarro-Sánchez P, Alonso-García I, Rumbo-Feal S, Galán-Sánchez F, Beceiro A, Arca-Suárez J, Oliver A, Bou G. Lasarte-Monterrubio C, et al. Among authors: beceiro a. J Antimicrob Chemother. 2022 Sep 30;77(10):2809-2815. doi: 10.1093/jac/dkac241. J Antimicrob Chemother. 2022. PMID: 35904000
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
Alonso-García I, Vázquez-Ucha JC, Lasarte-Monterrubio C, González-Mayo E, Lada-Salvador P, Vela-Fernández R, Aja-Macaya P, Guijarro-Sánchez P, Rumbo-Feal S, Muíño-Andrade M, Fernández-González A, Martínez-Guitián M, Beceiro A, Rodríguez-Iglesias M, Oliver A, Arca-Suárez J, Galán-Sánchez F, Bou G. Alonso-García I, et al. Among authors: beceiro a. J Antimicrob Chemother. 2023 May 3;78(5):1195-1200. doi: 10.1093/jac/dkad062. J Antimicrob Chemother. 2023. PMID: 36918743
In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification.
Gato E, Guijarro-Sánchez P, Alonso-García I, Pedraza-Merino R, Conde A, Lence E, Rumbo-Feal S, Peña-Escolano A, Lasarte-Monterrubio C, Blanco-Martín T, Fernández-González A, Fernández-López MDC, Maceiras R, Martínez-Guitián M, Vázquez-Ucha JC, Martínez-Martínez L, González-Bello C, Arca-Suárez J, Beceiro A, Bou G. Gato E, et al. Among authors: beceiro a. Int J Antimicrob Agents. 2023 Oct;62(4):106935. doi: 10.1016/j.ijantimicag.2023.106935. Epub 2023 Aug 3. Int J Antimicrob Agents. 2023. PMID: 37541530
Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa.
González-Pinto L, Blanco-Martín T, Alonso-García I, Rodríguez-Pallares S, Outeda-García M, Gomis-Font MA, Fraile-Ribot PA, Vázquez-Ucha JC, González-Bello C, Beceiro A, Oliver A, Bou G, Arca-Suárez J. González-Pinto L, et al. Among authors: beceiro a. J Antimicrob Chemother. 2024 Nov 4;79(11):3023-3028. doi: 10.1093/jac/dkae326. J Antimicrob Chemother. 2024. PMID: 39287983
Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.
Blanco-Martín T, López-Hernández I, Aracil B, González-Pinto L, Aja-Macaya P, Alonso-García I, Rodríguez-Pallares S, Sánchez-Peña L, Outeda-García M, Pérez-Vázquez M, Vázquez-Ucha JC, Beceiro A, Pascual Á, Bou G, López-Cerero L, Oteo-Iglesias J, Arca-Suárez J; GEMARA-SEIMC/CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT). Blanco-Martín T, et al. Among authors: beceiro a. Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0092424. doi: 10.1128/aac.00924-24. Epub 2024 Oct 9. Antimicrob Agents Chemother. 2024. PMID: 39382274
93 results